Axon to Release Third Quarter 2025 Earnings on November 4, 2025

AXON (Nasdaq: AXON), the global public safety technology leader, today announced that it will report third quarter 2025 financial results after the market closes on Tuesday, November 4, 2025. AXON will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day.

The live webinar to discuss financial results, followed by Q&A, will be linked from Axon's investor relations website at https://investor.axon.com. An archived replay will be available after the call ends. 

Upcoming Conference Participation

The Company also announced that Axon will participate in the following upcoming conferences. If applicable, events will be webcast live and archived on Axon's investor relations website at https://investor.axon.com.

2025 RBC Global TIMT Conference, Tuesday, November 18, 2025
6th Annual Needham Tech Week, Thursday, November 20, 2025
UBS Global Technology and AI Conference, Tuesday, December 2, 2025
Barclays 23rd Annual Global Technology Conference, Thursday, December 11, 2025
Northland Capital Virtual Conference, Tuesday, December 16, 2025

About Axon

AXON (Nasdaq: AXON) is the global leader in public safety technology, relentlessly innovating to protect more lives in more places. Founder-led since 1993, AXON began with a mission to reimagine conflict in law enforcement and has grown into a global company serving everyone who takes on the responsibility of public safety, enterprise security, and national security — from first responders and governments to companies, frontline workers, and communities. Our trusted network connects TASER energy devices, cameras and sensors including body-worn, fixed and in-car cameras, drones and robotics, digital evidence and records management, real-time operations, immersive training, productivity tools, and AI-driven capabilities and insights. Designed to work seamlessly together, these solutions create a connected picture of safety that helps protect people and places with greater speed, clarity, and accountability.

Non-Axon trademarks are the property of their respective owners. Axon, TASER and the Delta Logo are trademarks of Axon Enterprise, Inc., some of which are registered in the US and other countries. For more information, visit www.axon.com/legal. All rights reserved.

Responsible Innovation at Axon

At Axon, innovation is inseparable from responsibility. We believe technology must serve humanity, and every product we build is designed to solve the real challenges our customers face in protecting their communities. That means developing solutions in close collaboration with the people who use them and grounding our work in transparency, fairness, accountability, and privacy. Our independent Ethics & Equity Advisory Council provides ongoing input and feedback that helps shape our approach, ensuring we remain thoughtful and aligned with community needs as technology evolves. Learn more at axon.com/responsibility.

Follow Axon here:

Note to Investors

Please visit http://investor.axon.com,
https://www.axon.com/press, https://x.com/axon_us and
https://www.facebook.com/Axon.ProtectLife/ where Axon discloses information about the company, its financial information and its business.

CONTACT:
Investor Relations
Axon Enterprise, Inc.
IR@axon.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/axon-to-release-third-quarter-2025-earnings-on-november-4-2025-302590570.html

SOURCE Axon

News Provided by PR Newswire via QuoteMedia

AXON
The Conversation (0)
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs) No approved MS DMTs have shown... Keep Reading...
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding sharesAwakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics... Keep Reading...
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, today is reporting its financial results and business highlights for the three and nine months ended... Keep Reading...
Awakn Life Sciences Signs MOU with NHS  and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Awakn Life Sciences Signs MOU with NHS and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase IIIAwakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and... Keep Reading...
awakn life sciences

Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway

Transaction concludes with the launch of "Awakn Clinics Oslo AS" as part of Awakn Life Sciences Nordic ExpansionAwakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic therapeutics (medicines and... Keep Reading...

Latest Press Releases

Related News